Assessing immunotherapy response: going beyond RECIST by integrating early tumor growth kinetics

Assessing immunotherapy response: going beyond RECIST by integrating early tumor growth kinetics

ObjectiveAssess the contribution of early tumor growth dynamics modeling to predict clinical outcomes in non-small cell lung cancer patients receiving immunotherapy, alongside standard RECIST 1.1 criteria.MethodsOur retrospective studies used data from 861 patients with advanced NSCLC enrolled in th...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mehdi Felfli, Alexandre Thinnes, Sebastien Jacques, Yan Liu, Antoine Iannessi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Immunology
Subjects:	growth rate non-small cell lung cancer immunotherapy RECIST 1.1 novel Gompertz model progression-free survival
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1470555/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A call for objectivity: Radiologists’ proposed wishlist for response evaluation in solid tumors (RECIST 1.1)
by: Kathleen Ruchalski, et al.
Published: (2024-11-01)

Dedicated software to harmonize the follow-up of oncological patients
by: Mathias Illy, et al.
Published: (2024-12-01)

Bioenergy potential of paper waste: Fungal pretreatment and kinetics modelling
by: Utibe A. Ofon, et al.
Published: (2025-01-01)

Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer
by: Hélène Poinot, et al.
Published: (2024-12-01)

DESCRIPCIÓN MATEMÁTICA DE LA FUNCIÓN GOMPERTZ APLICADA AL CRECIMIENTO DE ANIMALES
by: C. A. Martínez, et al.
Published: (2010-01-01)

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
by: Jianfeng Peng, et al.
Published: (2025-02-01)

Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study
by: Luigi Liguori, et al.
Published: (2024-11-01)

ROLE OF HETEROZYGOUS TUMOR SUPPRESSORS IN THE LIFE LONGEVITY OF DROSOPHILA MELANOGASTER
by: S. A. Kopyl, et al.
Published: (2015-01-01)

An oncogene regulating chromatin favors response to immunotherapy<subtitle>Oncogene CHAF1A and immunotherapy outcomes</subtitle>
by: Leqian Ying, et al.
Published: (2024-12-01)

Grey modeling method for approximate exponential sequence of optimizing initial condition
by: Yun YUE, et al.
Published: (2016-11-01)

Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients
by: Sandra García-Mulero, et al.
Published: (2023-12-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Grey Prediction of Mountainous Runoff of Datengxia Based on R/S Analysis
by: CUI Yanhua, et al.
Published: (2022-01-01)

Understanding and overcoming resistance to immunotherapy in genitourinary cancers
by: Sean T Evans, et al.
Published: (2024-12-01)

A Comparative Analysis of the Diffusion of Mobile Technologies in the Visegrad Four Using an ECM Model
by: Marcin Salamaga
Published: (2024-12-01)

LncRNA DDX11-AS1 promotes breast cancer progression by targeting the miR-30c-5p/MTDH axis
by: Yanting Li, et al.
Published: (2024-11-01)

Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
by: Maite Alvarez, et al.
Published: (2023-12-01)

Cryoablation synergizes with anti-PD-1 immunotherapy induces an effective abscopal effect in murine model of cervical cancer
by: Xiaoming Yang, et al.
Published: (2025-01-01)

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells
by: Guochen Li, et al.
Published: (2025-02-01)

LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis
by: Zi‐Hao Ke, et al.
Published: (2024-12-01)

Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis
by: Xinyan Hao, et al.
Published: (2025-01-01)

<i>IL-11</i> Expression in Systemic Sclerosis Is Dependent on Caspase-1 Activity but Does Not Increase Collagen Deposition
by: Caya M. McFalls, et al.
Published: (2024-10-01)

Comparison of treatment outcome between first‐line combination immunotherapy (anti‐PD‐L1 or anti‐PD1) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital
by: Danainut Naratornsirakul, et al.
Published: (2024-07-01)

Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non–Small Cell Lung Cancer With High Programmed Death-Ligand 1 Expression
by: Alvin H.K. Cheung, MBBS, PhD, et al.
Published: (2025-01-01)

A STUDY ON FORECASTING THE IMPACT OF COVID-19 ON EMERGENCY SERVICE IN A PUBLIC HOSPITAL
by: Şeyma Çelik Eroğlu, et al.
Published: (2022-07-01)

Targeted Delivery of BMS-1166 for Enhanced Breast Cancer Immunotherapy
by: Yu Z, et al.
Published: (2025-01-01)

Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma
by: Lin Zhang, et al.
Published: (2025-01-01)

Gompertz model with delays and treatment: Mathematical analysis
by: Marek Bodnar, et al.
Published: (2013-03-01)

Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening
by: Dan Zhao, et al.
Published: (2025-02-01)

Consolidation immunotherapy following concurrent chemoradiotherapy in a patient with sinonasal NUT carcinoma: a case report
by: Xiaotao Geng, et al.
Published: (2024-12-01)

CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma
by: Yizeng Fan, et al.
Published: (2025-02-01)

Harnessing m1A modification: a new frontier in cancer immunotherapy
by: Xinru Wang, et al.
Published: (2024-12-01)

Innovative immunotherapies and emerging treatments in type 1 diabetes management
by: Malek Zarei, et al.
Published: (2025-01-01)

DSN1 may predict poor prognosis of lower-grade glioma patients and be a potential target for immunotherapy
by: Yulong Jia, et al.
Published: (2024-12-01)

The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy
by: Jin Li, et al.
Published: (2024-12-01)

Research on anchor service life base on grey prediction model
by: Xinzheng Wang
Published: (2018-07-01)

Impact of Cryptocurrency Volatility on Stock Market Performance in Nigeria
by: Ibrahim Bello Abdullahi, et al.
Published: (2023-05-01)

A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy
by: Manqing Peng, et al.
Published: (2024-12-01)

Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma
by: Hao-Dong QIAO, et al.
Published: (2023-10-01)

Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy
by: Sonja Cotra, et al.
Published: (2024-11-01)